<scp> CD56 <sup>bright</sup> </scp> <scp>NK</scp> cells are negatively associated with antibody response to vaccination in people with multiple sclerosis on B‐cell‐depleting therapy
Time since ocrelizumab infusion was not associated with protective vaccination. Evaluation of B-cell and CD56<sup>bright</sup> NK cell frequencies may provide a personalised strategy to stratify pwMS for vaccination and prophylaxis.
Authors
- Sebastian Sterling (ORCID: https://orcid.org/0000-0001-8567-7042)
- Matthew B. Roberts (ORCID: https://orcid.org/0000-0003-0869-6463)
- Makutiro G. Masavuli (ORCID: https://orcid.org/0000-0001-7287-6595)
- Stuart Turville (ORCID: https://orcid.org/0000-0003-1918-5343)
- P. Hurtado (ORCID: https://orcid.org/0000-0002-0913-7797)
- Christopher M. Hope (ORCID: https://orcid.org/0000-0001-8206-1939)
- Jacqueline C. Scaffidi
- Arthur Eng Lip Yeow (ORCID: https://orcid.org/0000-0003-1282-5635)
- James Zuiani
- Janakan Ravindran
- Anupriya Aggarwal
- Kevin Webb
- Joey Yap
- Simon C. Barry
- Anouschka Akerman
- Branka Grubor‐Bauk
- Matthew J Tunbridge
- Vanessa Milogiannakis
- Pravin Hissaria
- Griffith B Perkins
- Cheng Sheng Chai
Institutions
- South Australia Pathology (AU)
- Royal Adelaide Hospital (AU)
- Women's and Children's Hospital (AU)
- UNSW Sydney (AU)
- Basil Hetzel Institute (AU)
- SA Health (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Clinical & Translational Immunology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cti2.70079
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00